StockData
HCW Biologics Inc. logo

HCW Biologics Inc. (HCWB) company profile

HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.76−0.01 (-1.65%)

Close on Nov 18, 2026Market cap $1.40MP/E –Yield –

About HCW Biologics

Pharmaceutical Preparations, SIC 2834

HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel fusion immunotherapeutics to treat conditions driven by chronic inflammation. Its pipeline targets autoimmune and proinflammatory diseases, cancer, and senescence-associated dysplasia. The company designs its product candidates using two proprietary platforms, TOBI and TRBC. Its lead clinical candidate, HCW9302, is an injectable fusion protein complex being evaluated for alopecia areata. HCW Biologics also develops commercial-ready reagent molecules, including HCW9201 and HCW9206, which serve biopharmaceutical customers producing CAR-T and natural killer cell therapies for cancer and infectious diseases.

Operationally, the company conducts its early clinical trials across two active clinical trial sites located at The Ohio State University and the James A. Haley Veterans' Hospital. In addition, the firm partners with Beijing Trimmune Biotech Co., Ltd., which holds licensing rights to advance candidate therapies in China and retains worldwide rights for another program. The company's clinical activities and trials are based in the United States.

Summary of the business section of HCW Biologics's latest annual report, written by StockData.

Company profile

Company

Legal name
HCW Biologics Inc.
Headquarters
Miramar, FL
Address
2929 N Commerce Pkwy 33025
Phone
(954) 842-2024
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Crowe LLP, Indianapolis, Indiana

Stock & identifiers

Ticker
HCWB
Exchange
Nasdaq
IPO date
Jul 21, 2021
Shares outstanding
2M, Aug 12, 2026
Public float
$6.20M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-6 reverse, Jun 30, 2026; 1-for-40 reverse, Aug 18, 2025; 1-for-40 reverse, Apr 11, 2025
SEC CIK
1828673
CUSIP
40423R303
ISIN
US40423R3030
FIGI
BBG011769443
Share class FIGI
BBG0117694Z9
LEI
5299008ZJ4RXXTN04Z97
EIN
82-5024477

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Hing C. WongChief Executive Officer, Director125,845
Lee FlowersSVP of Business Development8,691
Rebecca ByamChief Financial Officer57,245
Scott T. GarrettDirector67,149
Gary M. WinerDirector4,075
Rick S. GreeneDirector2,066

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 21, 2021
Offer price
$8.00
Securities offered
7,000,000
Gross proceeds
$56.00M
Exchange
Nasdaq
First trading day
Jul 20, 2021
First-day close
$6.30-21.3%
Lock-up ends (est.)
Jan 16, 2022

“The initial public offering price is $8.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?